LAKE ZURICH, Ill., June 3, 2013 – Fresenius Kabi has been named NOVAPLUS® Pharmacy Supplier of the Year by Novation, a leading health care supply chain and contracting company for the more than 65,000 members of VHA Inc. and UHC, two national health care alliances, Children's Hospital Association, an alliance of the nation's leading pediatric facilities, and Provista, LLC.
The Novation award recognizes excellent service by Fresenius Kabi in providing the members served by Novation with critical drugs, particularly those affected by nationwide shortages. This is the second time in three years Fresenius Kabi has earned this award.
"We are pleased to recognize suppliers who go the extra mile to provide superior customer service and industry-leading value," said Pete Allen, area senior vice president of sourcing operations at Novation. "Fresenius Kabi is a great example of a supplier with these characteristics."
"At Fresenius Kabi, we understand the daily challenges our customers face in caring for critically ill patients, and we strive to set ourselves apart in a competitive pharmaceutical field through exceptional service and value-based partnerships," said John Ducker, president and CEO for Fresenius Kabi USA. "This award is a testament to the customer focus and teamwork of our employees. I am proud of them for this recognition knowing how hard they have worked to support our customers and the patients they serve."
About Fresenius Kabi
Fresenius Kabi (www.fresenius-kabi.com) is a leading global health care company that focuses on medicines and medical devices used to care for critically and chronically ill patients inside and outside the hospital. The company's products include intravenous specialty and generic medicines, infusion therapies, clinical nutrition, and blood-transfusion technologies. Its roots go back more than 100 years to the founding of our parent company, Fresenius SE, in Bad Homburg, Germany, where the company is headquartered today.
Founded in 1998, Novation is a leading health care supply chain expertise and contracting company for the more than 65,000 members of VHA Inc. and UHC, two national health care alliances, Children's Hospital Association, an alliance of the nation's leading pediatric facilities, and Provista, LLC. Novation provides alliance members with sourcing services, as well as information and data services. Based in Irving, Texas, Novation develops and manages competitive contracts with more than 600 suppliers. VHA, UHC, and Provista members used Novation contracts to purchase approximately $43 billion in 2012. Novation earned the coveted Ethics Inside Certification® from Ethisphere Institute, a leading international think tank dedicated to the research and promotion of best practices in corporate ethics and compliance. Novation was also named on Ethisphere's World's Most Ethical Companies list, and is the only company in the health care industry to earn both distinctions for two consecutive years. To learn more about Novation, please visit www.novationco.com and follow @NovationNews.
The statements contained in this news release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this news release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the demand, supply and distribution of our products. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, but are not limited to, the availability and pricing of ingredients used in the manufacture of pharmaceutical products and the ability to successfully manufacture products in a time-sensitive and cost effective manner. Additional relevant information concerning risks can be found in the Fresenius Kabi Pharmaceuticals Holding, Inc. 10-K for the fiscal year ending December 31, 2010 and other documents the company has filed with the Securities and Exchange Commission. The information contained in this news release is as of the date of this release. Fresenius Kabi Pharmaceuticals Holding, Inc. does not assume any obligation to update or revise these forward-looking statements to conform the statement to actual results, new information, developments or changes in the Company's expectations.
Senior Director, Communications & Government Affairs
Fresenius Kabi USA